You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: 102

    The overall objective of the proposed research is to develop and conduct clinical translation of a novel visualization technology that provides minimally invasive surgeons the ability to visualize normally invisible internal anatomy together with organ surfacesThe technology addresses a long standing need in minimally invasive laparoscopic surgery to see inside and around a structure before dissec ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: r

    Project Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax spores are readily found in nature or produced in the laboratoryare resistant to harsh conditionsand can survive for a long time in the environmentThe microscopic spores could be formulated in powder ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Editing for Hemophilia Gene Therapy

    SBC: GENVEC, INC.            Topic: 100

    Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: 102

    Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Polyionic Papillomavirus like Particles VLP for the Treatment of HPV oropharyngeal squamous cell carcinomas OPCs

    SBC: PATHOVAX LLC            Topic: 102

    The broader impact commercial potential of PathoVax s STTR phase I proposal is to improve outcomes of cancer immuno therapy utilizing a vaccine formulation combining an immunogenic chimeric virus like particle cVLP vaccine with FDA approved immune check point inhibitors PathoVax proposes to develop this technology for treatment of human papillomavirus HPV associated cancers However cancer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Zika viral pseudoinfectious virus as Zika vaccine candidate

    SBC: Tengen Biomedical Co            Topic: NIAID

    Executive Summary of Predicate SBIR/STTR Phase I Grant and Team TenGen Biomedical Co. and Howard University received an STTR Phase I grant (5R41AI129119-02) from the National Institute of Allergy and Infectious Diseases (NIAID) in 2017. The overall objective of our predicate STTR Phase I grant is to develop a safe, effective, and affordable Zika vaccine based on the novel concept of the third gene ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government